Drug intelligence / Profile preview

antilymphoblast globulin + azathioprine + prednisone

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination immunosuppressive therapy consisting of antilymphoblast globulin (ALG), azathioprine, and prednisone. This regimen was commonly used in transplantation medicine, particularly for renal transplant recipients, to prevent organ rejection. Antilymphoblast globulin targets and depletes T lymphocytes, azathioprine interferes with DNA synthesis in immune cells, and prednisone provides anti-inflammatory and immunosuppressive effects through glucocorticoid receptor binding.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on antilymphoblast globulin + azathioprine + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on antilymphoblast globulin + azathioprine + prednisone.

Explore the full profile